Sigma-Aldrich Mevastatin. ≥95% (HPLC), HMG-CoA reductase inhibitor, solid. 50 mg

An antibiotic that acts as a potent inhibitor of HMG-CoA reductase, thus suppresses Ras farnesylation. Inhibitor of myoblast fusion. Causes cell cycle arrest in late g₁ phase. May induce bone morphogenic protein-2 (BMP-2). This product requires activation for use in cell culture and cell-free assay systems. To activate, treat with ethanol solution with 1 N NaOH and then neutralize with 1 N HCl to pH 7.2 (see Keyomarsi, K . et Al. 1991).

This is an inactive form which may require activation for use with isolated cells depending upon the application. To activate, treat with NaOH in ethanol and then neutralize to pH 7.2.

Cell permeable: no

Primary Target
HMG-CoA reductase

Product does not compete with ATP.

Reversible: no

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.

Sugiyama, M., et Al. 2000. Biochem. Biophys. Res. Commun.271, 688.
Hug, T., et Al. 1995. Pflugers Archiv. Eur. J. Physiol.429, 682.
Belo, R.S., et Al. 1993. Mol.Cell. Biochem.126, 159.
McLeish, K.R., et Al. 1993. Biochem. Biophys. Res. Commun.197, 763.
Keyomarsi, K., et Al. 1991. Cancer Res. 51, 3602.
Jackson, J.H., et Al. 1990. Proc. Natl. Acad. Sci. USA 87, 3042.
Kita, T., et Al. 1980. J. Clin. Invest. 66, 1094.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)